Sensus Healthcare, Inc., a Boca Raton, Fla.-based a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that it is set to join the Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective before the U.S. market opens June 25.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell U.S. Indexes primarily by objective, market-capitalization rankings, and style attributes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider.
“We are pleased to be included in the Russell Microcap Index,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We believe inclusion in the Russell Microcap Index will increase our visibility in the financial marketplace and potentially broaden our shareholder base as we continue to harness our SRT technology in effectively and safely treating oncological and non-oncological skin conditions and grow our aesthetic dermatology business.”
Sensus uses a proprietary low-energy x-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100 and SRT-100 Vision. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus recently launched Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.